HLX03

adalimumab biosimilar · Shanghai Henlius Biotech Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HLX03, covering 2025-08-13 to 2025-08-13. Get the full timeline:

Most recent: Clinical Trial Update: Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis [Phase 3]